J. Goldman & Co’s iShares Biotechnology ETF IBB Stock Holding History

J. Goldman & Co’s Portfolio IBB Stock Details IBB Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$5.07M	Buy	+30,000	New	+$5.13M	0.15%	183
2025 Q2	–	Sell	-40,000	Closed	-$5.12M	–	537
2025 Q1	$5.12M	Buy	40,000 +18,900	+90%	+$2.56M	0.13%	206
2024 Q4	$2.79M	Buy	+21,100	New	+$2.97M	0.07%	245
2022 Q3	–	Sell	-30,000	Closed	-$3.53M	–	428
2022 Q2	$3.53M	Buy	+30,000	New	+$3.56M	0.17%	142
2016 Q2	–	Sell	-90,000	Closed	-$7.82M	–	368
2016 Q1	$7.82M	Buy	+90,000	New	+$8.05M	0.49%	61

Other funds holding IBB

Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return

Citigroup New York $235B AUM 32.99% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

BNP Paribas Financial Markets Paris, France $206B AUM 31.61% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return

Envestnet Asset Management Chicago, Illinois $374B AUM 17.66% 1-Year Est. Return

Raymond James Financial St Petersburg, Florida $324B AUM 22.36% 1-Year Est. Return

Commerce Bank Kansas City, Missouri $20.7B AUM 23.76% 1-Year Est. Return

Wells Fargo San Francisco, California $530B AUM 22.01% 1-Year Est. Return

J. Goldman & Co's IBB Position: Q1 2026 in Review

J. Goldman & Co opened a new position in iShares Biotechnology ETF (IBB) in Q1 2026: 2,301 shares worth $389K. The stake represents 0.01% of the portfolio and ranks #537 among its holdings. This is a return to the name: J. Goldman & Co previously reported a position in IBB as recently as Q2 2025.

J. Goldman & Co first reported a position in IBB in Q1 2016 and has held it in 9 quarters since. The position peaked at $1.37M in Q2 2024. 917 funds tracked by Wall St. Rank hold IBB as of Q1 2026.

J. Goldman & Co held 2,301 shares of iShares Biotechnology ETF worth $389K as of Q1 2026.
iShares Biotechnology ETF was a new J. Goldman & Co position in Q1 2026.
iShares Biotechnology ETF made up 0.01% of J. Goldman & Co's portfolio in Q1 2026, its #537 holding.
J. Goldman & Co first reported a position in iShares Biotechnology ETF in Q1 2016 and has held it in 9 quarters since.
J. Goldman & Co's iShares Biotechnology ETF position peaked at $1.37M in Q2 2024.
917 funds tracked by Wall St. Rank held iShares Biotechnology ETF as of Q1 2026.

Based on J. Goldman & Co's 13F filing for Q1 2026, filed 15 May 2026.